Twist Bioscience Corporation Stock

Equities

TWST

US90184D1000

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
28.36 USD -0.74% Intraday chart for Twist Bioscience Corporation -13.22% -23.06%
Sales 2024 * 293M Sales 2025 * 354M Capitalization 1.65B
Net income 2024 * -180M Net income 2025 * -159M EV / Sales 2024 * 5.04 x
Net cash position 2024 * 174M Net cash position 2025 * 139M EV / Sales 2025 * 4.27 x
P/E ratio 2024 *
-9.29 x
P/E ratio 2025 *
-10.8 x
Employees 919
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.22%
More Fundamentals * Assessed data
Dynamic Chart
Twist Bioscience Corporation Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations CI
Transcript : Twist Bioscience Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM
Twist Bioscience Corporation Launches IVDR-Compliant Precision Dx Products for Whole Exome Sequencing CI
Twist Bioscience Announces Partnership With Element Biosciences, Launches Liquid Biopsy Kit MT
Twist Bioscience Corporation and Element Biosciences, Inc. Announce Collaboration to Develop Twist for Element, Exome 2.0 Plus Comprehensive Exome Spike-In Workflow for Element?s AVITI System CI
Twist Bioscience Corporation Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications CI
Scotiabank Adjusts Twist Bioscience's Price Target to $43 From $30, Maintains Sector Outperform Rating MT
Twist Bioscience Corporation Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT CI
Sector Update: Health Care Stocks Steady Premarket Friday MT
Twist Bioscience's Fiscal Q1 Net Loss Widens, Revenue Rises; Fiscal 2024 Revenue Guidance Lifted MT
Transcript : Twist Bioscience Corporation, Q1 2024 Earnings Call, Feb 02, 2024
Earnings Flash (TWST) TWIST BIOSCIENCE CORPORATION Reports Q1 Revenue $71.5M, vs. Street Est of $67.6M MT
Twist Bioscience Corporation Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024 CI
Twist Bioscience Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Twist Bioscience Corporation Updates Earnings Guidance for the Full Fiscal Year 2024 CI
More news
1 day-0.74%
1 week-13.22%
Current month-17.34%
1 month-16.17%
3 months-16.22%
6 months+65.36%
Current year-23.06%
More quotes
1 week
27.86
Extreme 27.86
31.07
1 month
27.86
Extreme 27.86
36.92
Current year
27.86
Extreme 27.86
43.21
1 year
11.46
Extreme 11.46
43.21
3 years
11.46
Extreme 11.46
144.14
5 years
11.46
Extreme 11.46
214.07
10 years
11.46
Extreme 11.46
214.07
More quotes
Managers TitleAgeSince
Founder 69 13-02-03
Chief Executive Officer 50 13-03-31
Director of Finance/CFO 47 Jan. 04
Members of the board TitleAgeSince
Director/Board Member 64 16-10-31
Director/Board Member 67 18-09-30
Director/Board Member 63 13-09-30
More insiders
Date Price Change Volume
24-04-18 28.36 -0.74% 807,821
24-04-17 28.57 -0.14% 837,768
24-04-16 28.61 -2.15% 871,062
24-04-15 29.24 -4.69% 864,282
24-04-12 30.68 -6.12% 1,092,011

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
28.57 USD
Average target price
40.12 USD
Spread / Average Target
+40.44%
Consensus